None listed
Conditions
Interventions
Drug, Medical Device : In both experimental and control groups, 12 acupuncture treatments are administered three times a week for four weeks. The experimental group is given 900 mg of gabapentin per d
Sponsors
Daegu Oriental Hospital of Daegu Haany University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women between 19 and 80 years old. 2. Patients whose chemotherapy ended and peripheral neuropathy caused by chemotherapy lasted more than three months. 3. Patients with peripheral neuropathy Grade 1 or higher 4. Those who can follow up during the test period and agree to follow the limits 5. Subject who has written consent from the patient or a legal representative
Exclusion criteria
Exclusion criteria: 1. A person who receives other alternative treatments, such as high dose vitamin therapy, for treatment of peripheral neuropathy 2. People with peripheral neuropathy due to other organic causes such as diabetes 3. Patients with advanced and metastatic cancer 4. Those who are taking medicines that can affect peripheral neuropathy (such as tricyclic antidepressants, carbamazepine, gabapentine, opiate, conventional medicine, painkillers, etc.). 5. People who require surgical treatment due to neurological symptoms of sensory or motor paralysis 6. People who have liver function tests and kidney function tests exceed 3 times the normal level. 7. Patients with reduced immunity who may be infected during acupuncture treatment. leukopenia (WBC <4,000 / ?), or neutropenia (neutro <1,500 / ?) 8. Patients with blood clotting disorders or taking heparin or coumarin. thrombocytopenia (platelet <50,000 / ?) 9. A person with heart disease or its history. 10. People with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. 11. Pregnant or lactating women, women of childbearing potential who do not agree to contraception using medically proven methods (eg condoms, loops, femdomes, etc.) during the trial period. 12. Patients with acute pancreatitis and those who are hypersensitive to gabapentin. 13. Persons who were deemed unfit to participate in clinical trials physically and mentally.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NPSI (Neuropathic Pain Symptom Inventory), VAS (Visual Analogue score) | — |
Secondary
| Measure | Time frame |
|---|---|
| EORTC QLQ CIPN 20 (European Organization for Research and Treatment of Cancer Quality of life questionnaire Chemotherapy-Induced Peripheral Neuropathy 20) | — |
Countries
Korea, Republic of
Contacts
Public Contacthyun jung jung
Daegu Oriental Hospital of Daegu Haany University
Outcome results
None listed